Does Rapamycin Slow Aging in Humans?

Not yet proven. Rapamycin (sirolimus) reliably extends lifespan in mice, and a one-year randomized trial in healthy adults found that low, once-weekly doses were tolerated about as well as placebo. But no human study has shown that rapamycin slows aging, delays age-related disease, or extends life. It is FDA-approved only for kidney transplant rejection and a rare lung disease. Any use for aging is off-label and investigational.

What This Means

Rapamycin is a prescription drug that blocks a protein called mTOR, the mechanistic target of rapamycin. mTOR acts as a nutrient sensor inside cells, signaling when to grow and divide and when to slow down and repair. Blocking it mimics some of the biology of calorie restriction, which is why it became the leading candidate in aging research (Roark & Iffland, 2025).

The FDA label lists two approved uses: prevention of organ rejection after kidney transplant, and lymphangioleiomyomatosis (LAM), a rare progressive lung disease (Pfizer, 2022). Aging is not an approved indication for any drug, and the FDA does not currently treat aging itself as a disease. When people talk about "rapamycin for longevity," they mean off-label, low-dose, intermittent use that no regulator has reviewed for that purpose (Roark & Iffland, 2025).

The mouse data are real and repeatable. In a National Institute on Aging program run across three independent sites, rapamycin started at 600 days of age (roughly a 60-year-old human) extended lifespan by 14% in females and 9% in males (Harrison et al., 2009). Mice are not people, and that gap is the whole question.

Candidacy

There is no accepted candidacy standard for rapamycin as an anti-aging intervention because there is no accepted indication. Physicians may prescribe an approved drug off-label under their own clinical judgment, but that judgment has to be built on a full evaluation rather than a request.

Some groups should not take rapamycin outside a monitored trial. That includes anyone with an active or recurrent infection, a weakened immune system, upcoming surgery or a healing wound, liver disease, poorly controlled cholesterol or triglycerides, or pregnancy. Rapamycin is metabolized through the CYP3A4 pathway, so common medications, including some antibiotics, antifungals, and blood pressure drugs, can raise or lower its levels (Pfizer, 2022).

The people most likely to be discussed as candidates are healthy adults in midlife or later with normal labs, no immune concerns, and a clear understanding that the benefit is unproven. Even then, the responsible answer is often to wait for better data.

Clinical Evaluation

An evaluation for any longevity-focused medication starts the same way as any other: history, current medications and supplements, and a physical exam. For rapamycin specifically, baseline labs matter because the drug's known effects at transplant doses include elevated cholesterol and triglycerides, low platelets, anemia, and changes in kidney and liver markers (Pfizer, 2022).

A reasonable baseline includes a complete blood count, a lipid panel, fasting glucose or HbA1c, liver and kidney function, and a review of vaccination status and infection history. If a physician does prescribe, the same labs are repeated at intervals. Symptom tracking matters too. In the PEARL trial, gastrointestinal complaints were the one category reported more often on rapamycin than on placebo (Moel et al., 2025).

Available Options

Rapamycin sits at the experimental end of a much longer list. The options with the strongest evidence for healthy aging are not drugs at all: regular aerobic and resistance exercise, adequate sleep, not smoking, keeping blood pressure, lipids, and blood sugar in range, and staying current on vaccines. None of these are novel. All of them have decades of outcome data that rapamycin does not.

Next are FDA-approved therapies for specific age-related conditions, prescribed for that condition rather than for aging: statins for cardiovascular risk, hormone therapy for menopausal symptoms in appropriate patients, and bone-density medications for osteoporosis. These have labels, defined risks, and a monitoring standard.

Then come the investigational geroscience drugs. Rapamycin and its close relatives (rapalogs such as everolimus) are the most studied. Metformin is being tested in the TAME trial for delaying age-related disease. Senolytic drugs, which aim to clear aged cells, are in early trials. A large placebo-controlled trial of rapamycin in companion dogs (TRIAD) is under way through the Dog Aging Project and will be the first rigorous lifespan test of the drug outside a laboratory (Coleman et al., 2025). All of these remain experimental.

Finally, there is a large market of supplements and peptides sold as anti-aging. Most have not been tested in humans for that purpose, and none are FDA-reviewed for it.

Benefits, Limitations and Risks

The potential benefit is a drug that acts on a fundamental aging pathway rather than on one disease at a time. That is a real scientific idea with strong animal support. The limitation is that in humans it is still an idea.

The risks are better documented than the benefits. At transplant doses, the label lists adverse reactions occurring in 30% or more of patients, including peripheral swelling, high triglycerides, high blood pressure, high cholesterol, elevated creatinine, constipation, abdominal pain, diarrhea, headache, fever, urinary tract infection, anemia, nausea, joint pain, and low platelets. It also carries warnings for impaired wound healing, serious infections, liver injury, and mouth ulcers (Pfizer, 2022).

Low-dose weekly use is a different exposure, and PEARL reported adverse events at similar rates to placebo over 48 weeks. Two caveats apply. First, 114 people for one year cannot detect uncommon harms or anything that develops over a decade. Second, the trial used compounded rapamycin, which was later found to reach roughly one-third the blood concentration of the commercial tablet, so the effective doses were lower than the labeled 5 mg and 10 mg (Moel et al., 2025). Whether higher effective doses stay this quiet is unknown.

The largest human trials of an mTOR inhibitor for an aging-related outcome ended without a clear win. A phase 3 trial of RTB101 in 1,024 adults aged 65 and older did not meet its primary endpoint of reducing symptomatic respiratory infections, even though an earlier phase 2b study had looked promising (Mannick et al., 2021).

What the Evidence Shows

What the evidence does establish: rapamycin extends lifespan in mice, including when started late in life, across multiple labs (Harrison et al., 2009). Short courses of an mTOR inhibitor improved influenza vaccine response by about 20% in older adults (Mannick et al., 2014). Low-dose, intermittent rapamycin for 48 weeks was tolerated similarly to placebo in healthy adults, and women on the 10 mg dose showed small improvements in lean mass and self-reported pain (Moel et al., 2025).

What the evidence does not establish: that rapamycin extends human lifespan, delays any age-related disease in people, or changes biological age. PEARL's primary outcome, visceral fat, did not change at all. Its secondary findings were modest, came from small subgroups, and were not corrected for the number of comparisons made. The trial did not measure any validated aging marker (Moel et al., 2025). The phase 3 RTB101 trial was negative on its primary endpoint (Mannick et al., 2021). Long-term safety in healthy people is unknown (Roark & Iffland, 2025).

The honest summary is that rapamycin is the most promising aging drug in animals and an unanswered question in humans. Wanting the answer to be yes is not the same as having it.

Recovery / Next Steps

There is no recovery period because there is no procedure. The practical next step for anyone curious about rapamycin is a conversation with a physician who will review the evidence with you rather than simply write the prescription. If you are already taking it, bring the source, the dose, and your most recent labs to your next visit so it can be documented and monitored like any other medication.

If the goal is healthier aging rather than rapamycin specifically, the evaluation usually points somewhere more established first: cardiovascular risk, metabolic health, muscle mass and strength, sleep, and, where indicated, hormone levels.

Orlando Considerations

Florida allows licensed physicians to prescribe FDA-approved drugs off-label, and rapamycin is available by prescription at Orlando pharmacies. Compounded versions are also marketed, but the PEARL findings on reduced absorption are a reason to ask which formulation is being prescribed and why. If you are enrolling in a longevity trial, the nearest sites are typically at academic centers; ask whether remote participation is offered, since PEARL itself was run as a decentralized trial.

Frequently Asked Questions

Is rapamycin FDA-approved for anti-aging?

No. Rapamycin (sirolimus) is FDA-approved to prevent kidney transplant rejection and for lymphangioleiomyomatosis, a rare lung disease. Aging is not an approved indication, and any use for that purpose is off-label (Pfizer, 2022).

Has rapamycin been shown to extend human lifespan?

No. Lifespan extension has been demonstrated in mice, not people. The longest placebo-controlled human study of low-dose rapamycin ran for 48 weeks and measured safety and body composition, not longevity (Moel et al., 2025).

What dose do longevity studies use?

PEARL tested 5 mg and 10 mg of compounded rapamycin once weekly, but the compounded product was later found to deliver about one-third the blood concentration of commercial tablets. There is no validated dose for aging, and the transplant label doses are not the same regimen (Moel et al., 2025).

What are the most common side effects at low doses?

In PEARL, adverse events were similar to placebo overall, with gastrointestinal complaints reported somewhat more often on rapamycin. At higher transplant doses, high lipids, mouth ulcers, slowed wound healing, and infections are documented on the label (Moel et al., 2025; Pfizer, 2022).

Should I take rapamycin if I am healthy?

That is a decision for you and a physician who has reviewed your history and labs. The evidence supports curiosity, not confidence. Exercise, sleep, and control of blood pressure, lipids, and blood sugar have far stronger data for healthy aging.

This article is for general education and is not medical advice. Rapamycin is a prescription drug that is not FDA-approved for aging, and its use for that purpose is investigational. Any medication decision requires an evaluation, laboratory testing where indicated, and ongoing monitoring. This article does not describe a treatment offered at PrimeCell. Individual results vary. Treatment options are discussed after a medical evaluation.

Medically reviewed by Kenny Chantasi, DO.

References

Coleman, A. E., Creevy, K. E., Anderson, R., Reed, M. J., Fajt, V. R., Aicher, K. M., Atiee, G., Barnett, B. G., Baumwart, R. D., Boudreau, B., Cunningham, S. M., Dunbar, M. D., Ditzler, B., Ferguson, A. M., Forsyth, K. K., Gambino, A. N., Gordon, S. G., Hammond, H. K., Holland, S. N., . . . Kaeberlein, M. (2025). Test of Rapamycin in Aging Dogs (TRIAD): Study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project. GeroScience, 47(3), 2851–2877. https://doi.org/10.1007/s11357-024-01484-7

Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., Pahor, M., Javors, M. A., Fernandez, E., & Miller, R. A. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460(7253), 392–395. https://doi.org/10.1038/nature08221

Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., Lonetto, M. A., Maecker, H. T., Kovarik, J., Carson, S., Glass, D. J., & Klickstein, L. B. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 6(268), 268ra179. https://doi.org/10.1126/scitranslmed.3009892

Mannick, J. B., Teo, G., Bernardo, P., Quinn, D., Russell, K., Klickstein, L., Marshall, W., & Shergill, S. (2021). Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: Phase 2b and phase 3 randomised trials. The Lancet Healthy Longevity, 2(5), e250–e262. https://doi.org/10.1016/S2666-7568(21)00062-3

Moel, M., Harinath, G., Lee, V., Nyquist, A., Morgan, S. L., Isman, A., & Zalzala, S. (2025). Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging, 17(4), 908–936. https://doi.org/10.18632/aging.206235

Pfizer. (2022). Rapamune (sirolimus) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021083s069s070,021110s087s088lbl.pdf

Roark, K. M., & Iffland, P. H., II. (2025). Rapamycin for longevity: The pros, the cons, and future perspectives. Frontiers in Aging, 6, 1628187. https://doi.org/10.3389/fragi.2025.1628187

Last medically reviewed: September 4, 2026.

Related reading

• Does NAD+ Therapy Really Work for Anti-Aging?
• What a Peptide Specialist Actually Does
• How Much Does Peptide Therapy Cost?
• When Should You Start Hormone Replacement Therapy?

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.